Abstracts

Different Immunologic and Virologic Contexts for HIV-Associated Lymphoma in the CNICS Cohort

Background: Pathobiology of HIV-associated lymphoma may be changing in the era of effective antiretroviral therapy (ART). Lymphoma incidence is increased soon after ART, perhaps due to the immune reconstitution inflammatory syndrome (IRIS). Methodology: In the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS), we characterized patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma…

Predicting Survival of HIV-Infected Patients With Liver Cancer: The SHILCA Score and Staging Model

Background: Published staging and survival models of hepatocellular carcinoma (HCC), such as Barcelona-Clinic-Liver-Cancer (BCLC), Cancer-of-the-Liver-Italian-Program (CLIP), or Model-to-Estimate-Survival-in-Ambulatory-Patients-with-HCC (MESIAH) have been shown to predict survival in HIVnegative patients. They have not yet been validated in HIV-infected patients with HCC. Furthermore, HIV viral load as well as performance status have both been shown to independently predict…

Monoclonal Gammopathy and HIV-1 Infection: Evolution With Highly Active Antiretroviral Therapy

Background: Monoclonal gammopathies (MG) associated with HIV infection are frequent but their significance and evolution are uncertain in this population with a high risk of lymphoproliferative disorder. Our aim was to describe the evolution of MG in HIV-infected subjects under highly active antiretroviral therapy (HAART). Methodology: Retrospective study of HIV-1 infected adults, with a monoclonal…

Mechanisms by Which Negative Elongation Factor (NELF) Establishes and Maintains HIV Latency

Background: Understanding events which contribute to HIV latency is critical for improving current treatments and potentially eradicating HIV infection. Events that contribute to HIV transcriptional latency include repressive chromatin structure, transcriptional interference, the inability of Tat to recruit P-TEFb and poor processivity of RNA polymerase II (RNAP II). Previously, we have established an important role…

Differential Role of Bromodomain Proteins in HIV-1 Latency

Background: Small molecules targeting bromodomain (BRD) proteins, a well-conserved class of transcriptional regulators distinguished by the presence of bromodomains, have recently emerged as novel epigenetic therapeutics in hematological and virological disease. Bromodomains are small helical interaction modules that specifically bind acetylated lysines in histones and nonhistone proteins. We recently tested the effect of bromodomain inhibitors…

JAK Inhibitors Tofacitinib and Ruxolitinib Block T-cell Activation Mediated HIV Replication

Background: Despite the successful suppression of plasma viremia, persistent immune activation and inflammation in HIV infected is associated to HIV persistence and increased morbidity. Targeting immune activation/inflammation using JAK inhibitors represents a rationale way to reduce inflammationdriven residual viral replication and/or viral persistence due to homeostatic proliferation. Tofacitinib and ruxolitinib are FDA-approved Jak1/2 inhibitors for…

The NCOR2-Nurr1-CoREST Axis Impairs HIV Reactivation in Latently Infected Microglial Cells

Background: Whereas the incidence of HIV-associated dementia (HAD) has declined due to successful anti-retrovirals treatment, prevalence of milder forms of HAD, which include asymptomatic neurocognitive impairment (ANI) and minor neurocognitive disorder (MND) has increased. Both ANI and MND are part of what is known as HIV-associated neurocognitive disorders (HAND). However, the molecular mechanisms explaining regulation…

HIV-1 Reactivation and Autophagy Inhibition Synergize to Cell Death via Amino Acid Deprivation

Background: Reactivation of latent provirus is considered a critical approach in modern strategies to purge latent HIV reservoir. Although histone deacetylase inhibitors (HDACi) demonstrated promising results in HIV-1 virus reactivation, the killing of the infected cells, which appears to be a key step in the elimination of HIV reservoir, remains an issue. Recently the cellular…

The Tat Inhibitor Cortistatin A Suppresses Transcription and Reactivation of HIV Latent Cells

Background: Despite the immense success of HIV anti-retroviral therapy (ART) to reduce replication to very low levels, it fails to eradicate the virus. HIV persists in latently and productively infected CD4+T cells in infected subjects undergoing ART. Current therapies are unable to inhibit reactivation of transcription from latently infected resting cells as well as production…